אורטיקריה - פרס כספי גבוה מובטח למרפא.
דיון מתוך פורום רפואת משפחה
שלום וברכה. במסגרת מאמצינו בחיפוש מרפא, ברצונינו לפנות לכל מי שיוכל לסייע בידינו למצא מרפא לביתינו. ביתינו בת 27 סובלת ממחלת האורטיקריה מזה 4 שנים. ההבחנה נקבעה chronic urticaria . היא עברה סדרת בדיקות מקיפה הן בהדסה והן בארה"ב. לא נמצא הגורם. אף כי ניסתה דיאטות חריפות לא השתפר מצבה. חייה תלויים בסטירואידים הגורמים לה לתופעות לוואי קשות. אנו משפחה אמידה המוכנה לשלם פרס כספי גבוה ומכובד למי שייסע בידינו להביא לביתינו מרפא. או לפחות הפסקת התלות בסטירואידים. אנו מבטיחים פרס גם למי שיביא לנו מידע על קיומו של טיפול בחו"ל. בכבוד רב משפ' סטולפר
בקישוריות הבאות לגביי מומחים בנושא מארצות הברית http://www.njc.org/MSU/09n6MSU_Chronic_Urticaria.html Allergy Foundation of America Florida Chapter, Inc 11700 N. 58th Street, Suite J, Tampa FL 33617 (813) 983-0244 http://www.aafaflorida.org/archives/chronic_urticaria_may_98.htm המומחה יוכל גם להעזר במקורות הבאים From Pediatric News Sinus Infection Often at Root of Chronic Urticaria Mary Ann Moon [Pediatric News 32(6):36, 1998. © 1998 International Medical News Group.] WASHINGTON -- Patients with chronic urticaria may be harboring a sinus infection that's causing or exacerbating their skin condition, Dr. K.C. Bergeron said at the annual meeting of the American Academy of Allergy, Asthma, and Immunology. Occult infections have been implicated in chronic urticaria before, but no studies assessing the prevalence of sinusitis in patients with the disorder have been done to date. Dr. Bergeron and associates at Vanderbilt University Medical Center, Nashville, Tenn., determined the prevalence of sinus infection in a group of 91 patients with chronic urticaria attending their allergy clinic. The investigators used recently developed coronal computed tomography, which is more sensitive than other techniques at detecting sinusitis. The 55 females and 36 males in the study were aged 10-72 years. Fifty-four (59%) were found to have sinusitis. Of the 53 whose sinus infections were treated -- typically with 10-14 days of antibiotic therapy and oral corticosteroids -- 21 reported that the treatment also induced long-term resolution of urticaria. Treating the sinusitis thus improved urticaria in 23% of the total group. http://www.haps.nsw.gov.au/education/infosheets/urticaria.html Chronic Urticaria About 8% of patients with systemic lupus erythematous (SLE) initially present with urticaria. SLE should be considered in patients with chronic urticaria, especially if other clinical features suggestive of systemic autoimmunity are present. Autoimmune thyroiditis can be associated with chronic urticaria, and should be tested for in the appropriate clinical context. A recent spate of reports have suggested that Helicobacter pylori (H. pylori) infection may be implicated in some cases of urticaria, with antibiotic therapy resolving the condition. Serological screening for H. pylori is probably only indicated if there are associated dyspeptic symptoms. Other systemic disorders associated with urticaria include rheumatoid arthritis, systemic sclerosis, and chronic infections, but in practice these conditions are found only rarely and should only be investigated if there are other suggestive clinical features. Autoimmune Chronic Urticaria Up to 60% of patients with chronic urticaria have demonstrable histamine-releasing activity in their serum, due to a heterogeneous group of molecules such as IL-1, IL-3 and GM-CSF released from activated lymphocytes, monocytes, neutrophils and fibroblasts. 50% of these patients with histamine-releasing activity have IgG autoantibodies directed against epitopes on the extracellular portion of the a -subunit of the high-affinity IgE receptor (Fce R-Ia ) on the surface of mast cells and basophils. Rarely, the autoantibodies are targeted directly against IgE molecules. While these patients have an identical clinical presentation to antibody-negative cases, the identification of patients with autoimmune urticaria may be of therapeutic utility, as some of these patients with severe disabling disease have responded to immunomodulation with intravenous immunoglobulin or plasmapheresis.